Simplifying susceptibility testing

dRAST™ is a rapid AST platform that identifies optimal antimicrobial after a positive blood culture, while other conventional systems take 2-3 days

Here’s how it works


Automated AST optimises your workflow, with less than 1 minute of hands-on time to operate


Consistent and accurate identification ensures optimal antimicrobial treatment


Only 4 hours from positive blood culture to result reduces mortality, complications, and relapse


Detect earlier.
Treat faster.

Simplifying susceptibility testing


Rapid AST with
MIC & SIR direct from PBC


Full Expert System on board
with dynamic algorithm


Easy to use interface
with low hands-on time

Random access

Continuous loading for optimal handling of urgent care patients


Incorporating international guidelines & recommendations: EUCAST, CLSI &


LIS BI-directional with easy Bacteria
Identification integration

Patended 96 wells plate with dried antibiotics


Gram Positive / Gram Negative panels for positive blood culture

Get consistent, reliable results into the right hands


Proprietary algorythms, databases, expert EUCAST ruler, and state-of-the-art imaging technology automates MIC determination and SIR interpretation, delivering objective reporting directly into the right hands

MIC: Minimum Inhibitory
SIR: Susceptible, Intermediate and Resistant

Re-inventing classic AST
Shorten time to treatment with automated testing

dRASTTM utilises modern microfluidic technology to automate conventional reference methods:

1. Broth microdilution
Re-invented with 96-well plates for optimal phenotyping MIC

2. Diffusion
Liquid-solid media brings fixed bacteria to interact with multi-drug panel

dRAST™ is the solution to help you care for sepsis patients

Frequently Asked Questions

Gram Negative

on dRASTTM GN panel, we feature 4 drug mixes:


-Cefotaxime / Clavulanic acid


-Ceftazidime / Clavulanic acid

Based on CLSI decision matrix, dRASTTM will analyze the difference of MIC within these 4 drug mixes.

dRASTTM will therefore produce an ESBL result : Negative or Positive based on MIC differences

With 8 wells on Imipenem and 8 wells on Meropenem, we have a very clear MIC result which clearly indicates if the bacteria is resistant or not to carbapenem drugs. This also applies to Pseudomonas aeruginosa and Acinetobacter baumannii

dRASTTM does not feature an AmpC flag per se but with the 3 cephalosporin drugs present on GN panel (Cefepime, Cefotaxime, Ceftazidime), dRASTTM provides a clear susceptibility information regarding any resistance towards cephalosporin drugs.

Gram Positive

For Staphylococcus aureusStaphylococcus lugdunensis Staphylococcus saprophyticus, we feature Oxacillin and Cefoxitin Screen which clearly indicates the difference between MRSA & MSSA.For other Staphylococcus species, resistance is determined on Oxacillin MIC results. Cefoxitin Screen is less susceptible for these species.

Yes. If the strain is resistant to Erythromycin, in this case, dRASTTM considers the iCLI well on GP panel (mix of Erythromycin/Clindamycin). If any growth on iCLI well, iCLI appears positive and resistance to Clindamycin is detected

With 7 wells on Vancomycin, MIC result is produced on Vancomycin providing clear indication of VRE.

With 7 wells on Teicoplanin and 7 wells on Vancomycin, MIC result is produced on dRASTTM providing clear indication of GISA presence.

Other interesting content

Looking for something else? You might be interested in this as well.

Culture Media

SSI Diagnostica holds many years of experience within production of culture media. Our production facilities are modern with high capacity and ISO 13485 certified.

Read more

Rapid Tests – Fast and easy aid in the diagnosis

Rapid tests are lateral flow immunoassays for qualitative detection.

Read more


Please, reach out if you have questions, comments or requests.